metaPreg - Sumatriptan during pregnancy

Sumatriptan

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.00 [0.87, 1.14]	0%	5 studies	57,007	4,840	not evaluable	ROB	-
Major congenital malformations	1.07 [0.39, 2.88]	25%	4 studies	122	2,583	not evaluable	ROB	-
7 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.60 [0.43, 5.97]	79%	3 studies	103	691	not evaluable	ROB	-
Low birth weight (< 2500g)	0.92 [0.64, 1.33]	0%	3 studies	80	1,267	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Postpartum hemorrhage	0.49 [0.25, 0.96]	-	1 study	82	104	not evaluable	ROB	3.51 [.; 1.25]
1 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
1 non statistically significant endpoints reported in only one study
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Early intrauterine death (< 22 weeks)	1.06 [0.68, 1.67]	26%	4 studies	735	4,196	not evaluable	ROB	-
Elective/induced termination of pregnancy	1.02 [0.50, 2.05]	0%	3 studies	162	4,198	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks)	0.91 [0.16, 5.06]	0%	3 studies	20	4,198	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study